MCID: BSL007
MIFTS: 66

Basal Cell Carcinoma malady

Categories: Genetic diseases, Cancer diseases, Skin diseases, Respiratory diseases, Rare diseases

Aliases & Classifications for Basal Cell Carcinoma

About this section

Aliases & Descriptions for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 11 13 66
Basal Cell Neoplasm 11 25 66
Basal Cell Cancer 11 48 66
Malignant Basal Cell Tumor 11 66
Experimental Organism Basal Cell Carcinoma 66
Nodulo-Ulcerative Basal Cell Carcinoma 66
Malignant Basal Cell Neoplasm 11
Basal Cell Carcinoma of Skin 11
 
Basal Cell Carcinoma Nos 11
Basal Cell Neoplasm Nos 11
Epithelioma Basal Cell 11
Carcinoma, Basal Cell 37
Neoplasms, Basal Cell 37
Carcinoma Basal Cell 48
Basal Cell Tumor 11
Rodent Ulcer 11

Classifications:



Summaries for Basal Cell Carcinoma

About this section
Wikipedia:69 Basal cell carcinoma (BCC) (also known as basalioma or basal cell cancer), is the most common skin... more...

MalaCards based summary: Basal Cell Carcinoma, also known as basal cell neoplasm, is related to basal cell carcinoma 1 and basal cell carcinoma 7. An important gene associated with Basal Cell Carcinoma is PTCH2 (Patched 2), and among its related pathways are Glypican 3 network and Central carbon metabolism in cancer. The drug fluorouracil has been mentioned in the context of this disorder. Affiliated tissues include skin, breast and lung, and related mouse phenotypes are taste/olfaction and no phenotypic analysis.

Disease Ontology:11 A skin carcinoma affecting basal cells.

Related Diseases for Basal Cell Carcinoma

About this section

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 6
Basal Cell Carcinoma 5 Basal Cell Carcinoma 4
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm basal cell carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 260)
idRelated DiseaseScoreTop Affiliating Genes
1basal cell carcinoma 134.6PTCH1, PTCH2, SMO
2basal cell carcinoma 733.1CTNNB1, GLI1, PTEN, SHH, SMO, TP53
3basal cell nevus syndrome33.1GLI1, GLI2, PTCH1, PTCH2, SHH, SMO
4medulloblastoma30.2CTNNB1, GLI1, PTCH1, PTCH2, SHH, SMO
5learning disability30.1MC1R, TP53, TYR
6nodular basal cell carcinoma12.3
7superficial basal cell carcinoma12.3
8infundibulocystic basal cell carcinoma12.3
9morpheaform basal cell carcinoma12.3
10pigmented basal cell carcinoma12.3
11adenoid basal cell carcinoma12.2
12clear cell basal cell carcinoma12.2
13sarcomatoid basal cell carcinoma12.2
14infiltrative basal cell carcinoma12.2
15cystic basal cell carcinoma12.2
16metatypical basal cell carcinoma12.2
17micronodular basal cell carcinoma12.2
18fibroepithelial basal cell carcinoma12.2
19basal cell carcinoma, multiple12.1
20anal margin basal cell carcinoma12.1
21external ear basal cell carcinoma12.1
22vulva basal cell carcinoma12.1
23scrotum basal cell carcinoma12.1
24follicular basal cell carcinoma12.1
25signet ring basal cell carcinoma12.1
26basal cell carcinoma 212.0
27basal cell carcinoma 312.0
28basal cell carcinoma 612.0
29basal cell carcinoma 512.0
30basal cell carcinoma 412.0
31penis basal cell carcinoma12.0
32sebaceous basal cell carcinoma12.0
33bazex syndrome11.8
34rombo syndrome11.5
35adamantinoid basal cell epithelioma11.1
36homocysteinemia10.8GLI2, PTCH1
37glomangioma10.8CYLD, TP53
38camera marugo cohen syndrome10.8GLI2, PTCH1, TP53
39brainstem intraparenchymal clear cell meningioma10.7PTCH1, SUFU, TP53
40pelizaeus-merzbacher disease in female carriers10.7GLI2, PTCH1, SHH
41x-linked dominant intellectual disability-epilepsy syndrome10.7GLI2, PTCH1, SHH
42x-linked intellectual disability, golabi-ito-hall type10.7GLI2, PTCH1, SHH
43x-linked intellectual disability, porteous type10.7GLI2, PTCH1, SHH
44homocystinuria without methylmalonic aciduria10.7GLI2, PTCH1, SHH
45pleomorphic rhabdomyosarcoma10.7GLI1, PTCH1, TP53
46microphthalmia with coloboma 510.7GLI2, PTCH1, SHH
47renal pelvis inverted papilloma10.7PTCH1, TP53
48mental retardation, autosomal recessive 4910.7CYLD, PTCH1, TP53
49nodular medulloblastoma10.7GLI2, PTCH1, SUFU
50dysautonomia, familial10.7GLI1, GLI2, SHH

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to basal cell carcinoma

Symptoms for Basal Cell Carcinoma

About this section

Drugs & Therapeutics for Basal Cell Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Erivedge16 42 VISMODEGIB Genentech January 2012
FDA Label: Erivedge
Disease/s that Drug Treats:basal cell carcinoma
Indications and Usage:16 ERIVEDGE (vismodegib) capsule is a hedgehog pathway inhibitor indicatedfor the treatment of adults with metastatic basal cell carcinoma, or with locallyadvanced basal cell carcinoma that has recurred following surgery or who arenot candidates for surgery, and who are not candidates for radiation. (1)
DrugBank Targets:14 1. Smoothened homolog
Mechanism of Action:16 
Target: hedgehog (Hh) signaling pathway
Action: innhibitor
FDA: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibitsSmoothened, a transmembrane protein involved in Hedgehog signal transduction.
2
Intron A16 42 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:16 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:14 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:16 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Odomzo16 42 SONIDEGIB PHOSPHATE Novartis Jul-15
FDA Label: Odomzo
Disease/s that Drug Treats:locally advanced basal cell carcinoma
Indications and Usage:16 ODOMZO is a hedgehog pathway inhibitor indicated for the treatment ofadult patients with locally advanced basal cell carcinoma (BCC) that hasrecurred following surgery or radiation therapy, or those who are notcandidates for surgery or radiation therapy. (1)
DrugBank Targets: -
Mechanism of Action:16 
Target: Smoothened
Action: inhibitor
FDA: Sonidegib is an inhibitor of the Hedgehog pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane proteininvolved in Hedgehog signal transduction.

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 152)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
TriamcinolonePhase 4, Phase 2463124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
2
FluorouracilPhase 4, Phase 3, Phase 2, Phase 1172851-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
3triamcinolone acetonidePhase 4, Phase 2463
4
ImiquimodPhase 4, Phase 3, Phase 2, Phase 113599011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
5vitamin dPhase 4, Phase 21607
6
Proton pump inhibitorsPhase 41057
Synonyms:
 
PPIs
7
Aminolevulinic acidPhase 4, Phase 3, Phase 2, Phase 1, Phase 0150106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
8interferonsPhase 4, Phase 3, Phase 2, Phase 12112
9
EverolimusPhase 4, Phase 2, Phase 1, Phase 01863159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
10
MiconazolePhase 4, Phase 2, Phase 3, Phase 1, Phase 0357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
11
TacrolimusPhase 4, Phase 21058104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
12
sirolimusPhase 4, Phase 2, Phase 1, Phase 0186353123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
13
AcetylcysteinePhase 4304616-91-112035
Synonyms:
(2R)-2-acetylamino-3-Sulfanylpropanoic acid
(R)-2-acetylamino-3-Mercaptopropanoic acid
(R)-Mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
 
Fluprowit
L-Acetylcysteine
L-alpha-acetamido-beta-Mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-ACETYL-L-cysteine
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
14CalcifediolPhase 44019356-17-3
15
Nitric OxidePhase 458510102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
16
ErgocalciferolNutraceuticalPhase 4, Phase 2121150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
17arginineNutraceuticalPhase 4393
18
DocetaxelApproved May 1996Phase 3, Phase 1, Phase 21880114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
19
BevacizumabPhase 3, Phase 1, Phase 21938216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
20
ZincPhase 321547440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
21
CisplatinPhase 3, Phase 2, Phase 1261415663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
22
IrinotecanPhase 3, Phase 2, Phase 1106297682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
23
OxaliplatinPhase 3, Phase 2, Phase 1136661825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
24
seleniumPhase 31717782-49-2
Synonyms:
Selanediide
Selenide
 
Selenide(2-)
Selenium
Selenium ion (Se2+)
25topoisomerase I inhibitorsPhase 3, Phase 2, Phase 11313
26
leucovorinPhase 3, Phase 2104758-05-9143, 54575
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
27
CarboplatinPhase 3, Phase 1, Phase 2194241575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
28pancreatic polypeptidePhase 320
29
Megestrol acetatePhase 364595-33-511683
Synonyms:
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17α-Acetoxy-6-dehydro-6-methylprogesterone
17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17α-acetoxyprogesterone
6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
 
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17α-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate
6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone
MGA
Megace
30
CevimelinePhase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
31
MegestrolPhase 3643562-63-819090, 3080587
Synonyms:
(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
3562-63-8
AC1L2DG3
C07120
CID19090
Chronopil
Chronopil (TN)
D008535
D08167
DB00351
 
EINECS 222-628-6
HSDB 3233
LS-118488
MGA
Megestrol (INN)
Megestrol Acetate
Megestrol [INN:BAN]
Megestrolo
Megestrolo [DCIT]
Megestrolum [INN-Latin]
Megestryl acetate
UNII-EA6LD1M70M
megestrol
32
EflornithinePhase 3, Phase 23570052-12-93009
Synonyms:
(RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid
.alpha.-DFMO HCl
2,5-diamino-2-(difluoromethyl)pentanoic acid
2,5-diamino-2-(difluoromethyl)pentanoic acid hydrate hydrochloride
2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride
2-(Difluoromethyl)-DL-ornithine
2-(Difluoromethyl)-DL-ornithine HCl
2-(Difluoromethyl)-DL-ornithine hydrochloride
2-(Difluoromethyl)-DL-ornithine monohydrochloride
2-(Difluoromethyl)-DL-ornithine monohydrochloride, monohydrate
2-(Difluoromethyl)-DL-ornithine monohydrochloride.monohydrate
2-(Difluoromethyl)ornithine
2-(Difluoromethyl)ornithine hydrochloride hydrate
67037-37-0
68278-23-9
70050-56-5
70052-12-9
70052-12-9 (Parent)
96020-91-6
96020-91-6 (mono-hydrochloride, monohydrate)
AC-388
AC-5497
AC1L1EYW
AC1L1M41
AC1L9B1G
BMS 203522
BRN 2250529
C07997
C6H12F2N2O2.HCl.H2O
CCRIS 3295
CCRIS 3718
CCRIS 5805
CHEBI:41948
CHEMBL1201037
CHEMBL536971
CID3009
CID441361
CID57004
CPP-1X
D,L-alpha-Difluoromethylornithine
D,L-alpha-Difluoromethylornithine hydrochloride
D00829
D07883
D193_SIGMA
DFMO
DFMO (growth regulator)
DFMO HCl
DFMO hydrochloride
DFMO hydrochloride hydrate
DL-.alpha.-Difluoromethylornithine
DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride
DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate
DL-alpha-(Difluoromethyl)ornithine
DL-alpha-Difluoromethylornithine
DL-alpha-Difluoromethylornithine hydrochloride
 
DL-alpha-Difluoromethylornithine hydrochloride hydrate
DL-alpha-Difluoromethylornithine, Hydrochloride
Difluoromethylornithine
Difluromethylornithine
EFLORNITHINE
EFLORNITHINE HYDROCHLORIDE
EINECS 269-532-0
EU-0100429
Eflornithine (INN)
Eflornithine HCl
Eflornithine [INN:BAN]
Eflornithine hydrochloride (USAN)
Eflornithine hydrochloride [USAN]
Eflornithine hydrochloride hydrate
Eflornithine hydrochloride monohydrate
Eflornithinum
Eflornithinum [Latin]
Eflornitina
Eflornitina [Spanish]
FT-0082608
FT-0082826
HSCI1_000267
I06-0316
I06-0530
LS-178282
LS-185084
LS-7332
LS-98405
Lopac0_000429
MDL 71,782 A
MDL 71782
MDL-71782A
MLS000069341
MLS001332583
MolPort-003-940-991
N-Difluoromethylornithine
NCGC00015316-03
NCGC00093850-01
NCGC00162152-01
NSC270295
NSC337250
Ornidyl
Ornidyl (TN)
Ornithine, 2-(difluoromethyl)-, monohydrochloride
RMI 71782
RMI-71782
SBB066102
SMR000058442
UNII-4NH22NDW9H
UNII-ZQN1G5V6SR
Vaniqa
alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid
alpha-(Difluoromethyl)-DL-ornithine
alpha-Difluoromethylornithine
alpha-Difluoromethylornithine hydrochloride
dfmo
α-difluoromethylornithine
33
FentanylPhase 3739437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
34
FluconazolePhase 2, Phase 317386386-73-43365
Synonyms:
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
86386-73-4
AC-428
AC1L1FRQ
AC1Q77FV
AKOS000280854
AbZ Brand of Fluconazole
Afungil
Alflucoz
Aliud Brand of Fluconazole
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
BIDD:GT0799
BRD-K05977355-001-02-6
BSPBio_003504
Baten
Beagyne
Bio-0041
Biocanol
Biozole
Biozolene
C13H12F2N6O
CCRIS 7211
CHEBI:46081
CHEMBL106
CID3365
CPD000471882
Canzol
Chemia Brand of Fluconazole
Cryptal
D00322
D015725
DB00196
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
DRG-0005
Diflazon
Diflucan
Diflucan (TN)
Diflucan, Trican, Alfumet, Fluconazole
Dimycon
DivK1c_001030
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc Hexal
Flucazol
FlucoLich
Flucobeta
Fluconazol
Fluconazol AL
Fluconazol AbZ
Fluconazol Isis
Fluconazol Stada
Fluconazol [Spanish]
Fluconazol ratiopharm
Fluconazol von ct
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazole & Bovine Lactoferrin
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole & hGCSF
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazolum
Fluconazolum [Latin]
Flucostat
 
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
Hexal Brand of Fluconazole
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
LS-1858
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mack Brand of Fluconazole
MolPort-000-883-859
MolPort-002-885-825
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
NINDS_001030
Neofomiral
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
S1331_Selleck
SAM002589905
SAT Brand of Fluconazole
SMR000471882
SPBio_001613
SPECTRUM1503975
STK619301
Silanes Brand of Fluconazole
Solacap
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
UNII-8VZV102JFY
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
ZINC00004009
Zemyc
Zoltec
Zonal
betapharm Brand of Fluconazole
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
fluconazole
nchembio.100-comp3
nchembio.65-comp15
ratiopharm Brand of Fluconazole
35
TretinoinPhase 3218302-79-45538
Synonyms:
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-trans Retinoic Acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
36
rituximabPhase 2, Phase 31611174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
37
histaminePhase 3100975614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
38
succinylcholinePhase 3, Phase 1154306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
39
Histamine PhosphatePhase 3100851-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
40
Darbepoetin alfaPhase 316811096-26-7, 209810-58-2
Synonyms:
 
Darbepoetin
Darbepoetin alfa,recombinant
41
DoxepinPhase 3131668-19-5667477, 667468
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
3607-18-9
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
AKOS001582771
Adapin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
Curatin
D07875
DB01142
DivK1c_000431
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin Hcl
Doxepin Hydrochloride,
Doxepin [USAN]
 
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepinum
Doxepinum [INN-Latin]
HSDB 3069
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
LS-174582
LS-61638
Lopac-D-4526
Lopac0_000339
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Quitaxon
SPBio_000206
SPBio_002325
Sinequan
Sinequan (TN)
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Spectrum_000805
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Zonalon
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
cis-doxepin
doxepin
42
VerteporfinPhase 386129497-78-5
Synonyms:
Verteporfin
 
Verteporfina
Verteporfinum
Vertéporfine
43
St. John's WortNutraceuticalPhase 33784082-80-4
Synonyms:
Common st johnswort flowering top
Common st. john's wort flowering top
Common st. john's wort herb
Common st. johnswort flowering top
Guanyejinsitao
Hyperici herba
Hypericum nachitschevanicum flowering top
Hypericum perforatum flowering top
 
Hypoxis hemerocallidea root extract
Klamath weed flowering top
Klamathweed flowering top
Powdered st. john's wort extract
Saint johns wort
St Johns Wort
St john's wort
St. johns wort
St. johnswort flowering top
44
ornithineNutraceuticalPhase 3, Phase 26770-26-86262
Synonyms:
(+)-S-Ornithine
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-2,5-diaminovaleric acid
(S)-Ornithine
(S)-a,D-Diaminovalerate
 
(S)-a,D-Diaminovaleric acid
(S)-alpha,delta-Diaminovaleric acid
(S)-ornithine
(S)-α,δ-diaminovaleric acid
5-Amino-L-Norvaline
L-(-)-Ornithine
L-Ornithine
45COLANutraceuticalPhase 3, Phase 1, Phase 21824
46TocopherolNutraceuticalPhase 3395
47
Vitamin CNutraceuticalPhase 348850-81-75785, 54670067
Synonyms:
(+)-Sodium L-ascorbate
(+)-ascorbate
(+)-ascorbic acid
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
3-Keto-L-gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
30208-61-8
33034_RIEDEL
33034_SIAL
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AA
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
AR-1J3435
Acid Ascorbic
Acide ascorbique
Acide ascorbique [INN-French]
Acido ascorbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
Antiscorbic Vitamin
Antiscorbic vitamin
Antiscorbutic Vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Arco-Cee
Arco-cee
Ascoltin
Ascoltin (TN)
Ascor-B.I.D.
Ascorb
Ascorbajen
Ascorbate
Ascorbic Acid
Ascorbic Acid, Monosodium Salt
Ascorbic acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
BPBio1_000363
BSPBio_000329
C-Level
C-Long
C-Quin
C-Span
C-Vimin
C00072
C6H8O6
CCRIS 57
CE-VI-Sol
CHEBI:29073
CHEMBL196
CID5785
Cantan
Cantaxin
Caswell No. 061B
Catavin C
Ce Lent
Ce lent
Ce-Mi-Lin
Ce-mi-lin
Ce-vi-sol
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-Caps TD
Cee-Caps Td
Cee-Vite
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-Caps TC
Cetane-Caps TD
Cetane-Caps Tc
Cetane-Caps Td
Cetane-caps TC
Cetane-caps TD
Cetebe
 
Cetemican
Cevalin
Cevatine
Cevex
Cevi-Bid
Cevi-bid
Cevimin
Cevital
Cevitamate
Cevitamic Acid
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
Ciamin
Cipca
Citriscorb
Citrovit
Colascor
Concemin
Cortalex
D00018
DB00126
Davitamon C
Dora-C-500
Duoscorb
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
HSDB 818
HiCee
Hicee
Hybrin
IDO-C
Ido-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina Askorbova
Kyselina askorbova
Kyselina askorbova [Czech]
L(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbate
L-(+)-Ascorbic Acid
L-(+)-Ascorbic acid
L-(+)-ascorbic acid
L-3-Ketothreohexuronic acid lactone
L-3-ketothreohexuronic acid
L-Ascorbate
L-Ascorbic Acid
L-Ascorbic acid
L-Ascorbic acid, free radical form
L-Lyxoascorbate
L-Lyxoascorbic Acid
L-Lyxoascorbic acid
L-Threo-ascorbic acid
L-Threoascorbic acid
L-Xyloascorbate
L-Xyloascorbic Acid
L-Xyloascorbic acid
L-ascorbate
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-ascorbic acid
L-threo-hex-2-enono-1,4-lactone
LS-145
Laroscorbine
Lemascorb
Liqui-Cee
Liqui-cee
MLS002153776
Magnesium Ascorbicum
Magnorbin
Meri-C
Meri-c
MolPort-001-792-501
Monodehydroascorbic acid
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
NCI-C54808
NSC 33832
Natrascorb
Natrascorb injectable
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
SMR001233160
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Sodascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100M
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamin- C
Vitamin-?C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
acide ascorbique
acidum ascorbicum
acidum ascorbinicum
antiscorbic vita min
ascor-b.i.d
ascorbate
ascorbic acid
bmse000182
cee-caps td
cevibid
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
gamma-Lactone L-threo-Hex-2-enonate
gamma-Lactone L-threo-Hex-2-enonic acid
l-ascorbic acid
l-threo-hex-1-eofuranos-3-ulose
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
roscorbi c
vitamin C
ácido ascórbico
48TocotrienolNutraceuticalPhase 3391
49
vitamin eNutraceuticalPhase 339259-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
50
DoxilApproved June 1999Phase 2167631703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin

Interventional clinical trials:

(show top 50)    (show all 321)
idNameStatusNCT IDPhase
1A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaApproved for marketingNCT01160250Phase 4
2Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After CurettageCompletedNCT00314756Phase 4
3Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)CompletedNCT00581425Phase 4
4Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell CarcinomaCompletedNCT00204555Phase 4
5Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant RecipientsCompletedNCT00129961Phase 4
6The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory BiomarkerCompletedNCT02666976Phase 4
7Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage MethylaminolevulinateRecruitingNCT01491711Phase 4
8Imiquimod 5% Cream for the Treatment of Periocular Basal Cell CarcinomaRecruitingNCT00803907Phase 4
9VISmodegib for ORbital and Periocular Basal Cell CarcinomaRecruitingNCT02436408Phase 4
10CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention TrialActive, not recruitingNCT00847912Phase 4
11Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.Active, not recruitingNCT01939977Phase 4
12N-Acetylcysteine and Arginine Administration in Diabetic PatientsTerminatedNCT00569465Phase 4
13Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% CreamCompletedNCT00189306Phase 3
14Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and CryosurgeryCompletedNCT01212562Phase 3
15Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell CarcinomaCompletedNCT00472108Phase 3
16A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell CarcinomaCompletedNCT00189241Phase 3
17Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell CarcinomaCompletedNCT00469417Phase 3
18Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin CancerCompletedNCT00066872Phase 3
19Metvix PDT in Patients With "High Risk" Basal Cell CarcinomaCompletedNCT00473343Phase 3
20Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell CarcinomaCompletedNCT01212549Phase 3
21A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma RecurrenceCompletedNCT00129519Phase 3
22Topical Green Tea Ointment in Treatment of Superficial Skin CancerCompletedNCT02029352Phase 2, Phase 3
23Fractional CO2 Laser Assisted Photodynamic TherapyCompletedNCT01260987Phase 2, Phase 3
24PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call CarcinomaCompletedNCT00472043Phase 3
25Aldara for the Treatment of Large and/or Multiple sBCCCompletedNCT00189280Phase 3
26Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin CancerCompletedNCT00007631Phase 3
27PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin CancerCompletedNCT00472459Phase 3
28Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
29Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
30Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
31Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
32Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
33Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin CancerCompletedNCT00005884Phase 3
34Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.CompletedNCT00272428Phase 3
35Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological ControlRecruitingNCT00663650Phase 3
36Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell CarcinomaRecruitingNCT02242929Phase 3
37Radiotherapy or Imiquimod in Complex Lentigo MalignaRecruitingNCT02394132Phase 3
38Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant ChemotherapyRecruitingNCT02445391Phase 3
39Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With TRecruitingNCT01640405Phase 3
40TREatment of degeNerative and Neoplastic Diseases With RituximabRecruitingNCT01277172Phase 2, Phase 3
41Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic TherapyActive, not recruitingNCT02144077Phase 3
42Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
43Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS SubjectsActive, not recruitingNCT01362140Phase 3
44Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.TerminatedNCT00049959Phase 3
45Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted PatientsTerminatedNCT01532453Phase 3
46Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00041171Phase 3
47Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell CarcinomasCompletedNCT01108094Phase 2
48Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)CompletedNCT01350115Phase 2
49Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell CarcinomaCompletedNCT00108121Phase 2
50A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome PatientsCompletedNCT00961896Phase 2

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: neoplasms, basal cell

Genetic Tests for Basal Cell Carcinoma

About this section

Genetic tests related to Basal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Basal Cell Carcinoma25

Anatomical Context for Basal Cell Carcinoma

About this section

MalaCards organs/tissues related to Basal Cell Carcinoma:

34
Skin, Breast, Lung, Kidney, Brain, Testes, Liver

Animal Models for Basal Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Basal Cell Carcinoma:

39 (show all 28)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000539410.0CTNNB1, GLI3, PTEN, SHH
2MP:00030128.5CTNNB1, GLI1, GLI2, GLI3, KIT, MC1R
3MP:00053978.3ASIP, CTNNB1, CYLD, HHIP, KIT, PTCH1
4MP:00053698.3CTNNB1, EDN1, GLI2, KIT, PTCH1, PTCH2
5MP:00011868.2ASIP, CTNNB1, GLI3, KIT, MC1R, PTCH1
6MP:00053898.2CTNNB1, GLI1, GLI2, GLI3, KIT, PTCH1
7MP:00053878.0ASIP, CTNNB1, CYLD, HHIP, KIT, PTCH1
8MP:00053778.0ASIP, CTNNB1, EDN1, GLI2, GLI3, KIT
9MP:00053677.7ASIP, CTNNB1, EDN1, GLI1, GLI3, KIT
10MP:00053887.7CTNNB1, CYLD, GLI1, GLI2, GLI3, HHIP
11MP:00020067.6ASIP, CTNNB1, CYLD, GLI1, KIT, MC1R
12MP:00053857.5ASIP, CTNNB1, EDN1, GLI3, KIT, PTCH1
13MP:00107717.5ASIP, CTNNB1, CYLD, GLI2, GLI3, KIT
14MP:00053817.4CTNNB1, CYLD, EDN1, GLI1, GLI2, GLI3
15MP:00053917.2ASIP, CTNNB1, GLI2, GLI3, HHIP, KIT
16MP:00028737.1ASIP, CTNNB1, CYLD, EDN1, GLI1, GLI2
17MP:00053827.1ASIP, CTNNB1, EDN1, GLI1, GLI2, GLI3
18MP:00053847.1ASIP, CTNNB1, CYLD, GLI1, GLI2, GLI3
19MP:00053867.0ASIP, CTNNB1, CYLD, GLI1, GLI2, KIT
20MP:00053806.9ASIP, CTNNB1, EDN1, GLI1, GLI2, GLI3
21MP:00053796.8ASIP, CTNNB1, CYLD, EDN1, GLI1, GLI2
22MP:00053716.7ASIP, CTNNB1, CYLD, GLI1, GLI2, GLI3
23MP:00053906.6ASIP, CTNNB1, EDN1, GLI2, GLI3, KIT
24MP:00053766.6ASIP, CTNNB1, CYLD, EDN1, GLI2, GLI3
25MP:00036316.3ASIP, CTNNB1, EDN1, GLI1, GLI2, GLI3
26MP:00107686.2ASIP, CTNNB1, CYLD, EDN1, GLI1, GLI2
27MP:00053786.1ASIP, CTNNB1, CYLD, EDN1, GLI1, GLI2

Publications for Basal Cell Carcinoma

About this section

Articles related to Basal Cell Carcinoma:

(show top 50)    (show all 1699)
idTitleAuthorsYear
1
PCR Quantification of D. folliculorum in Periocular Basal Cell Carcinoma. (27615600)
2016
2
A Case-Control Study of Involvement of Oxidative DNA Damage and Alteration of Antioxidant Defense System in Patients with Basal Cell Carcinoma: Modulation by Tumor Removal. (27057281)
2016
3
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. (25759019)
2015
4
Conservative treatment protocol of keratocystic odontogenic tumor: report of a case with nevoid Basal cell carcinoma syndrome and literature review. (25848161)
2015
5
Patient Preferences for Treatment of Basal Cell Carcinoma: Importance of Cure and Cosmetic Outcome. (26537095)
2015
6
Case of the month. Multiple odontogenic keratocysts in association with nevoid basal cell carcinoma syndrome (NBCCS). (24400412)
2013
7
Basal cell carcinoma margin delineation: is curettage useful? A surgical and histological study. (23216407)
2013
8
Regional variations of basal cell carcinoma incidence in the U.K. using The Health Improvement Network database (2004-10). (23701520)
2013
9
Pigmented Basal cell carcinoma: a clinical variant, report of two cases. (24551712)
2013
10
Mushroom-Like Giant Basal Cell Carcinoma on the Nasal Tip. (24372940)
2013
11
Epidemiology of basal cell carcinoma in Lithuania, 1996-2010. (23795568)
2013
12
Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. (23190903)
2013
13
Combined 585a88nm pulsed-dye and 1,064a88nm Nd:YAG lasers for the treatment of basal cell carcinoma. (24272664)
2013
14
Value of CD10 Expression in Differentiating Cutaneous Basal from Squamous Cell Carcinomas and Basal Cell Carcinoma from Trichoepithelioma. (23825889)
2013
15
Morphology of basal cell carcinoma in high definition optical coherence tomography: en-face and slice imaging mode, and comparison with histology. (22540280)
2013
16
Vismodegib (Erivedge) for basal cell carcinoma. (22777303)
2012
17
Risk factors for orbital exenteration in periocular basal cell carcinoma. (22709845)
2012
18
Adamantinoid basal cell carcinoma: a predictor of more-aggressive clinical behavior. (22551358)
2012
19
Treatment of nodular basal cell carcinoma with cryotherapy and reduced protocol of imiquimod. (23270198)
2012
20
Basal cell carcinoma of the prostate: a case report. (22656427)
2012
21
Genetic skin diseases predisposing to basal cell carcinoma. (22391625)
2012
22
Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. (22385074)
2012
23
Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. (22964973)
2012
24
Acute burn scar basal cell carcinoma. (20179483)
2010
25
The occurrence of keratocystic odontogenic tumours in nevoid basal cell carcinoma syndrome. (19767519)
2009
26
Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures. (18679421)
2008
27
A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. (18624836)
2008
28
SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. (18333897)
2008
29
The Delphi panel in the economic evaluation of photodynamic therapy for actinic keratosis and basal cell carcinoma: poor results? (17535242)
2007
30
Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. (17875873)
2007
31
A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. (17573890)
2007
32
Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the naevoid basal cell carcinoma syndrome. (16582078)
2006
33
A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma. (16121053)
2005
34
Germline mutations of the PTCH gene in Japanese patients with nevoid basal cell carcinoma syndrome. (15565302)
2005
35
Activation of expression of hedgehog target genes in basal cell carcinomas. (11348463)
2001
36
Cytokeratins as markers of follicular differentiation: an immunohistochemical study of trichoblastoma and basal cell carcinoma. (11801790)
2001
37
Eosinophilic pustular folliculitis in association with nevoid basal cell carcinoma syndrome. (11558878)
2001
38
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. (10699914)
2000
39
Immunohistochemical characterization of pleomorphic giant cells in basal cell carcinoma. (10487292)
1999
40
Transforming growth factor-beta and bcl-2 distribution patterns distinguish trichoepithelioma from basal cell carcinoma. (9256917)
1997
41
Molecular basis of the nevoid basal cell carcinoma syndrome. (9425597)
1997
42
Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light. (9420532)
1997
43
Duplicitous growth of infiltrative basal cell carcinoma: Analysis of clinically undetected tumor extent in a paired case-control study. (8646468)
1996
44
Failure of interferon alfa and isotretinoin combination therapy in the nevoid basal cell carcinoma syndrome. (8546496)
1996
45
Idiopathic CD4+ T-cell lymphocytopenia with verrucae, basal cell carcinomas, and chronic tinea corporis infection. (7962742)
1994
46
Severe irritant dermatitis mimicking a basal cell carcinoma. (6230178)
1983
47
Adenoid basal cell carcinoma of the vulva. (7185765)
1982
48
The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. (6177160)
1981
49
Multiple keratocysts of the jaws as a manifestation of the nevoid basal cell carcinoma syndrome: report of a case and its surgical management. (1075799)
1975
50
Pigmented basal-cell carcinoma in verrucous nevi. Report of 2 cases. (13785794)
1961

Variations for Basal Cell Carcinoma

About this section

Cosmic variations for Basal Cell Carcinoma:

8 (show top 50)    (show all 221)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM43582TP53skin,NS,carcinoma,basal cell carcinomac.454C>Tp.P152S0
2COSM17476PTCH1skin,NS,carcinoma,basal cell carcinomac.707G>Ap.W236*0
3COSM96958PTCH1skin,NS,carcinoma,basal cell carcinomac.1930C>Tp.P644S0
4COSM29054PTCH1skin,NS,carcinoma,basal cell carcinomac.387G>Ap.W129*0
5COSM17475PTCH1skin,NS,carcinoma,basal cell carcinomac.1292T>Ap.L431Q0
6COSM10728TP53skin,NS,carcinoma,basal cell carcinomac.839G>Ap.R280K0
7COSM44241TP53skin,NS,carcinoma,basal cell carcinomac.592G>Tp.E198*0
8COSM10768TP53skin,NS,carcinoma,basal cell carcinomac.535C>Tp.H179Y0
9COSM17467PTCH1skin,NS,carcinoma,basal cell carcinomac.1726C>Tp.Q576*0
10COSM17522PTCH1skin,NS,carcinoma,basal cell carcinomac.3586C>Tp.P1196S0
11COSM29033PTCH1skin,NS,carcinoma,basal cell carcinomac.2038G>Tp.E680*0
12COSM17483PTCH1skin,NS,carcinoma,basal cell carcinomac.1729-1G>Tp.?0
13COSM490HRASskin,NS,carcinoma,basal cell carcinomac.38G>Ap.G13D0
14COSM1716826STAT5Bskin,NS,carcinoma,basal cell carcinomac.1697G>Ap.R566Q0
15COSM10660TP53skin,NS,carcinoma,basal cell carcinomac.818G>Ap.R273H0
16COSM17519PTCH1skin,NS,carcinoma,basal cell carcinomac.463C>Tp.P155S0
17COSM10662TP53skin,NS,carcinoma,basal cell carcinomac.743G>Ap.R248Q0
18COSM17472PTCH1skin,NS,carcinoma,basal cell carcinomac.1249C>Tp.Q417*0
19COSM516KRASskin,NS,carcinoma,basal cell carcinomac.34G>Tp.G12C0
20COSM14464PTCH1skin,NS,carcinoma,basal cell carcinomac.1804C>Tp.R602*0
21COSM44435TP53skin,NS,carcinoma,basal cell carcinomac.96+1G>Ap.?0
22COSM12296TP53skin,NS,carcinoma,basal cell carcinomac.292C>Tp.P98S0
23COSM29048PTCH1skin,NS,carcinoma,basal cell carcinomac.1347+1G>Ap.?0
24COSM43837TP53skin,NS,carcinoma,basal cell carcinomac.843C>Gp.D281E0
25COSM17592PTCH1skin,NS,carcinoma,basal cell carcinomac.3605C>Tp.P1202L0
26COSM17453PTCH1skin,NS,carcinoma,basal cell carcinomac.3196G>Tp.E1066*0
27COSM26363PTCH1skin,NS,carcinoma,basal cell carcinomac.2446C>Tp.Q816*0
28COSM10656TP53skin,NS,carcinoma,basal cell carcinomac.742C>Tp.R248W0
29COSM17490PTCH1skin,NS,carcinoma,basal cell carcinomac.3584C>Tp.T1195I0
30COSM26377PTCH1skin,NS,carcinoma,basal cell carcinomac.3449+1G>Ap.?0
31COSM3942015SMOskin,NS,carcinoma,basal cell carcinomac.961G>Ap.V321M0
32COSM11152TP53skin,NS,carcinoma,basal cell carcinomac.700T>Cp.Y234H0
33COSM10794TP53skin,NS,carcinoma,basal cell carcinomac.796G>Ap.G266R0
34COSM564NRASskin,NS,carcinoma,basal cell carcinomac.35G>Ap.G12D0
35COSM17584PTCH1skin,NS,carcinoma,basal cell carcinomac.2105C>Tp.P702L0
36COSM17511PTCH1skin,NS,carcinoma,basal cell carcinomac.3583A>Tp.T1195S0
37COSM17598PTCH1skin,NS,carcinoma,basal cell carcinomac.550C>Tp.Q184*0
38COSM29147PTCH1skin,NS,carcinoma,basal cell carcinomac.1356T>Gp.Y452*0
39COSM13146SMOskin,NS,carcinoma,basal cell carcinomac.1604G>Tp.W535L0
40COSM17498PTCH1skin,NS,carcinoma,basal cell carcinomac.2033C>Tp.T678I0
41COSM520KRASskin,NS,carcinoma,basal cell carcinomac.35G>Tp.G12V0
42COSM14455PTCH1skin,NS,carcinoma,basal cell carcinomac.3590C>Tp.S1197F0
43COSM26365PTCH1skin,NS,carcinoma,basal cell carcinomac.475A>Tp.I159L0
44COSM10905TP53skin,NS,carcinoma,basal cell carcinomac.451C>Tp.P151S0
45COSM1651687PTCH1skin,NS,carcinoma,basal cell carcinomac.2557C>Tp.Q853*0
46COSM44097TP53skin,NS,carcinoma,basal cell carcinomac.530C>Tp.P177L0
47COSM17551PTCH1skin,NS,carcinoma,basal cell carcinomac.1396C>Tp.Q466*0
48COSM10863TP53skin,NS,carcinoma,basal cell carcinomac.833C>Tp.P278L0
49COSM43583TP53skin,NS,carcinoma,basal cell carcinomac.425C>Tp.P142L0
50COSM11449TP53skin,NS,carcinoma,basal cell carcinomac.388C>Tp.L130F0

Copy number variations for Basal Cell Carcinoma from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
125690899820526498279247MutationPTCHBasal cell carcinoma

Expression for genes affiliated with Basal Cell Carcinoma

About this section
Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for genes affiliated with Basal Cell Carcinoma

About this section

Pathways related to Basal Cell Carcinoma according to KEGG:

32
id Name KEGG Source Accession
1Basal cell carcinomahsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
idSuper pathwaysScoreTop Affiliating Genes
110.1PTCH1, SHH
29.7KIT, PTEN, TP53
3
Show member pathways
9.6GLI1, GLI3, HHIP, PTCH1
49.6GLI1, GLI2, PTCH1, SHH, SMO
5
Show member pathways
9.5PTCH1, PTCH2, SHH, SMO, WNT1
6
Show member pathways
9.5CTNNB1, KIT, PTEN, TP53
79.4CTNNB1, PTCH1, SMO, TP53, WNT1
8
Show member pathways
9.4CTNNB1, PTEN, TP53, WNT1
99.4CTNNB1, PTEN, SHH, SMO, TP53
10
Show member pathways
9.4GLI2, HHIP, PTCH1, PTCH2, SHH, SMO
119.1GLI1, GLI2, GLI3, PTCH1, SHH, SMO
129.0CTNNB1, CYLD, GLI1, GLI2, PTCH1, PTCH2
13
Show member pathways
8.9GLI1, GLI2, GLI3, HHIP, PTCH1, SHH
14
Show member pathways
8.9GLI1, GLI2, GLI3, PTCH1, PTCH2, SMO
15
Show member pathways
8.7GLI1, GLI2, GLI3, HHIP, PTCH1, PTCH2
16
Show member pathways
8.3CTNNB1, GLI1, KIT, PTCH1, PTCH2, PTEN
177.4CTNNB1, GLI1, GLI2, GLI3, HHIP, KIT
18
Show member pathways
6.6CTNNB1, CYLD, EDN1, GLI1, GLI2, GLI3
19
Show member pathways
6.2ASIP, CTNNB1, EDN1, GLI1, GLI2, GLI3

GO Terms for genes affiliated with Basal Cell Carcinoma

About this section

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1melanosome membraneGO:003316210.2TYR, TYRP1
2endocytic vesicle membraneGO:003066610.0PTCH1, SMO, WNT1
3ciliary baseGO:00975469.9GLI1, GLI2, GLI3, SUFU
4ciliary membraneGO:00601709.9HHIP, PTCH1, SMO
5axonemeGO:00059309.8GLI1, GLI2, GLI3
6primary ciliumGO:00723729.7GLI1, GLI2, GLI3, PTCH1, SMO, SUFU
7ciliary tipGO:00975429.6CYLD, GLI1, GLI2, GLI3, SMO, SUFU
8ciliumGO:00059299.5GLI1, GLI2, GLI3, SMO, SUFU

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 108)
idNameGO IDScoreTop Affiliating Genes
1notochord regressionGO:006003210.9GLI1, GLI2
2somite developmentGO:006105310.7PTCH1, SHH, SMO
3ventral midline developmentGO:000741810.7GLI1, GLI2, SHH
4cerebellar cortex morphogenesisGO:002169610.7GLI1, GLI2, SMO
5positive regulation of epithelial cell proliferation involved in prostate gland developmentGO:006076910.6CTNNB1, SHH
6smoothened signaling pathway involved in dorsal/ventral neural tube patterningGO:006083110.6GLI2, GLI3, PTCH1
7smoothened signaling pathway involved in ventral spinal cord interneuron specificationGO:002177510.6GLI2, GLI3, SUFU
8smoothened signaling pathway involved in spinal cord motor neuron cell fate specificationGO:002177610.6GLI2, GLI3, SUFU
9hindgut morphogenesisGO:000744210.6GLI2, GLI3, SHH
10anatomical structure developmentGO:004885610.5GLI2, GLI3, SHH
11regulation of smoothened signaling pathwayGO:000858910.5GLI1, GLI2, PTCH1
12positive regulation of protein import into nucleusGO:004230710.5GLI3, SHH, SMO
13smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferationGO:002193810.5GLI1, GLI2, SHH, SMO
14positive regulation of smoothened signaling pathwayGO:004588010.5GLI1, SHH, SMO
15cell fate specificationGO:000170810.5CTNNB1, SHH, SMO
16hindbrain developmentGO:003090210.4CTNNB1, GLI2, SHH
17dorsal/ventral neural tube patterningGO:002190410.4GLI2, PTCH1, SHH, SMO
18spinal cord dorsal/ventral patterningGO:002151310.4GLI2, GLI3, SHH, SUFU
19spinal cord motor neuron differentiationGO:002152210.4GLI2, GLI3, PTCH1, SHH
20epithelial tube branching involved in lung morphogenesisGO:006044110.3CTNNB1, HHIP, SHH
21renal system developmentGO:007200110.3CTNNB1, PTCH1, SHH, SMO
22melanocyte differentiationGO:003031810.3GLI3, KIT, TYRP1
23anatomical structure formation involved in morphogenesisGO:004864610.2GLI2, GLI3, SHH
24skin developmentGO:004358810.2CTNNB1, PTCH2, SHH, SUFU
25embryonic digit morphogenesisGO:004273310.2CTNNB1, GLI2, GLI3, SHH
26developmental growthGO:004858910.2GLI2, GLI3, SHH, SMO
27cell fate determinationGO:000170910.1CTNNB1, PTCH1, PTCH2
28negative regulation of smoothened signaling pathwayGO:004587910.1GLI3, HHIP, PTCH1, PTCH2, SUFU
29proximal/distal pattern formationGO:000995410.1CTNNB1, GLI1, GLI2, GLI3
30negative regulation of cell differentiationGO:004559610.0CTNNB1, GLI3, SHH, WNT1
31pattern specification processGO:000738910.0GLI2, GLI3, PTCH1, SHH, SMO
32lung developmentGO:00303249.9CTNNB1, GLI1, GLI2, GLI3, SHH
33T cell differentiation in thymusGO:00330779.9CTNNB1, GLI3, SHH, WNT1
34odontogenesis of dentin-containing toothGO:00424759.9CTNNB1, GLI2, GLI3, SHH, SMO
35melanin biosynthetic processGO:00424389.8ASIP, MC1R, TYR, TYRP1
36positive regulation of neuroblast proliferationGO:00020529.8CTNNB1, GLI3, SHH, SMO
37branching involved in ureteric bud morphogenesisGO:00016589.8CTNNB1, GLI3, PTCH1, SHH, WNT1
38regulation of cell proliferationGO:00421279.8CTNNB1, GLI3, KIT, PTCH1, SHH
39in utero embryonic developmentGO:00017019.6CTNNB1, EDN1, GLI2, GLI3, PTCH1, SMO
40smoothened signaling pathwayGO:00072249.5GLI1, GLI2, GLI3, HHIP, PTCH1, SHH
41canonical Wnt signaling pathwayGO:00600709.5CTNNB1, GLI1, PTEN, SHH, SMO, WNT1
42positive regulation of sequence-specific DNA binding transcription factor activityGO:00510919.4CTNNB1, EDN1, KIT, PTEN, WNT1
43cell proliferationGO:00082839.3CTNNB1, GLI2, PTEN, SHH, TP53, TYR
44pigmentationGO:00434739.2ASIP, KIT, MC1R, TYR, TYRP1
45heart developmentGO:00075079.1CTNNB1, EDN1, GLI2, GLI3, PTEN, SHH
46positive regulation of transcription, DNA-templatedGO:00458939.0CTNNB1, GLI1, GLI2, GLI3, PTCH1, SHH
47dorsal/ventral pattern formationGO:00099538.7CTNNB1, EDN1, GLI1, GLI2, GLI3, HHIP
48negative regulation of transcription from RNA polymerase II promoterGO:00001228.4CTNNB1, EDN1, GLI2, GLI3, PTCH1, SHH
49positive regulation of transcription from RNA polymerase II promoterGO:00459448.2CTNNB1, EDN1, GLI1, GLI2, GLI3, MC1R
50positive regulation of cell proliferationGO:00082847.9CTNNB1, EDN1, GLI1, GLI2, KIT, PTEN

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1hedgehog receptor activityGO:000815810.9PTCH1, PTCH2
2smoothened bindingGO:000511910.9PTCH1, PTCH2
3hedgehog family protein bindingGO:009710810.7HHIP, PTCH1, PTCH2
4morphogen activityGO:001601510.6SHH, WNT1
5patched bindingGO:000511310.5PTCH1, SHH, SMO
6copper ion bindingGO:000550710.3TP53, TYR, TYRP1
7transcription regulatory region DNA bindingGO:00442129.9CTNNB1, GLI1, GLI2, TP53, WNT1
8chromatin bindingGO:00036829.7CTNNB1, GLI1, GLI2, GLI3, TP53
9protein kinase bindingGO:00199019.6CTNNB1, CYLD, PTEN, SUFU, TP53
10protein bindingGO:00055155.8ASIP, CTNNB1, CYLD, EDN1, GLI1, GLI2

Sources for Basal Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet